Demonstrated a dramatic reduction of approximately 90% in anti-VEGF administration (injection) frequency compared to global competitors across all dose cohorts. Confirmed visual improvement effects correlating with dose increases... Demonstrated an 8-letter improvement in visual acuity in the high-dose group, proving the therapeutic potential of NG101 for vision improvement. Plans to obtain U.S. Phase 2b clinical trial approval in the first half of 2027. Reyon Pharmaceutical announced on the 1...

- Establishing a foundation for responsible cooperation through an over-the-counter (OTC) trade, following last years MOU for the joint development of hemostatic agents. - TR Biofab accelerates commercialization by securing a stable supply of Thrombin, a core material. - Reyon Pharmaceutical solidifies its strategic partnership and establishes a framework for mutual growth. TR Biofab and Reyon Pharmaceutical have further solidified their partnership, advancing beyond the joint development of he...

- Pursuing supply cooperation with overseas partners... Spurring entry into the global market - Based on its status as the domestic thrombin standard built on 60 years of finished drug foundation, aiming for KRW 29 billion in sales by 2029 and a 10% domestic market share alongside the new product Thrombin Plus Reyon Pharmaceutical, the only domestic producer of finished thrombin drugs, has officially launched its full-scale targeting of the global market for its core product, Thrombin. The comp...

- Partner Elisigen unveils the 44-week clinical results of the mid-dose cohort for NG101 for the first time at ASRS. - Proven to reduce wet macular degeneration injection frequency by 90% even at an ultra-low doseless than 10% of competitors doses. - Reyon Pharmaceutical secures exclusive manufacturing rights, greenlighting advanced GMP commercial production at its new Chungju plant. NG101, a next-generation pipeline co-developed by Reyon Pharmaceutical and its partner Elisigen, has unveiled ov...